Codexis Names Pharmaceutical Industry Veteran Bernard J. Kelley Chairman of the Board
01 December 2016 - 11:00PM
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company,
announces that Bernard J. Kelley has been named Chairman of the
Board, effective November 29, 2016. Mr. Kelley has served as a
Director of Codexis since April 2004. He has succeeded former
Board Chairman Thomas Baruch, who will continue as a Director and
has been named Codexis Chairman Emeritus, an honorary title to
recognize his contributions to the company.
“Bernie’s service on our Board of Directors, as well as his
impressive background in pharmaceutical manufacturing along with
senior management and financial operations acumen have been
instrumental in establishing Codexis as a leader in enzyme
development,” said Mr. Baruch. “We are delighted that as Chairman
of the Board he will continue to build and guide our strategic
vision to grow our current lines of business and to expand into
adjacent markets.”
“Tom Baruch has been instrumental in leading the Board since
Codexis was formed over fourteen years ago, and most recently
oversaw the company’s transformational growth back into the
pharmaceutical sector,” said John Nicols, Codexis President and
CEO. “On behalf of our entire organization, I want to recognize and
thank Tom for his legacy of leadership at Codexis.”
Prior to joining the Codexis Board, Mr. Kelley was President of
the Merck Manufacturing Division where he was responsible for
chemical, pharmaceutical and biological manufacturing and directed
the activities of corporate engineering and global procurement.
He also served as a member of the Merck Management Committee
through his retirement in 2003. Mr. Kelley previously served
as a Director of MAP Pharmaceuticals, Inc., a biotechnology company
focused on developing inhalation-based therapies, as well as a
Director of Aegis Analytical Corporation, an enterprise software
company. He holds a B.S. in engineering from the U.S. Naval
Academy.
About CodeEvolver® Protein Engineering Platform
Technology
Codexis’ proprietary CodeEvolver® protein engineering platform
enables the rapid development of custom-designed enzymes that are
highly optimized for a specific function. The CodeEvolver® platform
is comprised of proprietary methods for the optimization of
proteins through the design and generation of diverse genetic
libraries, automated screening techniques, algorithms for the
interpretation of screening data and predictive modelling.
The Codexis CodeEvolver® platform technology is covered by more
than 225 issued patents and pending patent applications
worldwide.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that
applies its technology to the development of biocatalysts for
commercial manufacture of pharmaceuticals and fine chemicals.
Codexis’ proven technology enables implementation of biocatalytic
solutions to meet customer needs for rapid, cost-effective and
sustainable manufacturing. For more information, see
www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements relating
to the election of Bernard J. Kelley as Chairman of the Board of
Directors and the expectation of Codexis to grow its current lines
of business and to expand into adjacent markets. You should not
place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties and other
factors that are, in some cases, beyond Codexis’ control and that
could materially affect actual results. Factors that could
materially affect actual results include Codexis’ dependence on its
licensees and collaborators; Codexis’ dependence on a limited
number of products and customers in its pharmaceutical business;
potential adverse effects to Codexis’ business if its customers’
pharmaceutical products are not received well in the markets;
Codexis’ ability to deploy its technology platform in new market
spaces; Codexis’ dependence on key personnel; Codexis’ ability to
compete may decline if it loses some of its intellectual property
rights; third party claims that Codexis infringes third party
intellectual property rights; and Codexis could face increased
competition if third parties misappropriate Codexis biocatalysts.
Additional factors that could materially affect actual results can
be found in Codexis’ Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 8, 2016 and in Codexis’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 8, 2016, including, in each case,
under the caption “Risk Factors.” Codexis expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
Codexis Contacts:
InvestorsLHAJody Cain,
310-691-7100jcain@lhai.com
MediaThat’s Nice LLCGuy Tiene,
212-366-4455Guy@thatsnice.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024